{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:48:11Z","timestamp":1792784891478,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"SHOW ('Stichting Hematologisch-Oncologisch Wetenschapsonderzoek') is a Dutch non-profit foundation that promotes scientific research in the field of hemato-oncology."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1038\/s41375-020-0875-0","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T21:02:36Z","timestamp":1590613356000},"page":"494-505","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Primary therapy and relative survival in classical Hodgkin lymphoma: a nationwide population-based study in the Netherlands, 1989\u20132017"],"prefix":"10.1038","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9364-2501","authenticated-orcid":false,"given":"Julia","family":"Driessen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9e M.","family":"Zijlstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieternella J.","family":"Lugtenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter J.","family":"Plattel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Jos\u00e9","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4767-6716","authenticated-orcid":false,"given":"Avinash G.","family":"Dinmohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,28]]},"reference":[{"key":"875_CR1","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","volume":"116","author":"M Sant","year":"2010","unstructured":"Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724\u201334.","journal-title":"Blood."},{"key":"875_CR2","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","volume":"84","author":"N Harris","year":"1994","unstructured":"Harris N, Jaffe E, Stein H, Banks P, Chan J, Cleary M, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361\u201392.","journal-title":"Blood."},{"key":"875_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/bjh.16290","volume":"189","author":"HLA Posthuma","year":"2020","unstructured":"Posthuma HLA, Zijlstra JM, Visser O, Lugtenburg PJ, Kersten MJ, Dinmohamed AG. Primary therapy and survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma: a population-based analysis in the Netherlands, 1993\u20132016. Br J Haematol. 2020;189:117\u201321.","journal-title":"Br J Haematol"},{"key":"875_CR4","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7","volume":"36","author":"G Bonadonna","year":"1975","unstructured":"Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin\u2019s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36:252\u20139.","journal-title":"Cancer."},{"key":"875_CR5","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","volume":"327","author":"GP Canellos","year":"1992","unstructured":"Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478\u201384.","journal-title":"N Engl J Med"},{"key":"875_CR6","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa022473","volume":"348","author":"V Diehl","year":"2003","unstructured":"Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin\u2019s disease. N Engl J Med. 2003;348:2386\u201395.","journal-title":"N Engl J Med"},{"key":"875_CR7","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","volume":"21","author":"A Engert","year":"2003","unstructured":"Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin\u2019s lymphoma: results of the HD8 trial of the German Hodgkin\u2019s Lymphoma Study Group. J Clin Oncol. 2003;21:3601\u20138.","journal-title":"J Clin Oncol"},{"key":"875_CR8","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1182\/blood-2004-04-1311","volume":"104","author":"DJ Straus","year":"2004","unstructured":"Straus DJ, Portlock CS, Qin J, Myers J, Zelenetz AD, Moskowitz CH, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004;104:3483\u20139.","journal-title":"Blood"},{"key":"875_CR9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1100340","volume":"365","author":"S Viviani","year":"2011","unstructured":"Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, et al. ABVD versus BEACOPP for Hodgkin\u2019s lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365:203\u201312.","journal-title":"N Engl J Med"},{"key":"875_CR10","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.2015.64.5648","volume":"34","author":"P Carde","year":"2016","unstructured":"Carde P, Karrasch M, Fortpied C, Brice P, Khaled H, Casasnovas O, et al. Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in Stage III to IV, international prognostic score >\/= 3, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 intergroup trial. J Clin Oncol. 2016;34:2028\u201336.","journal-title":"J Clin Oncol"},{"key":"875_CR11","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","volume":"32","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048\u201358.","journal-title":"J Clin Oncol"},{"key":"875_CR12","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","volume":"35","author":"M Andre","year":"2017","unstructured":"Andre M, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, et al. Early positron emission tomography response\u2013adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 Trial. J Clin Oncol. 2017;35:1786\u201394.","journal-title":"J Clin Oncol"},{"key":"875_CR13","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","volume":"372","author":"J Radford","year":"2015","unstructured":"Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372:1598\u2013607.","journal-title":"N Engl J Med"},{"key":"875_CR14","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1200\/JCO.19.00964","volume":"37","author":"M Fuchs","year":"2019","unstructured":"Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, et al. Positron emission tomography\u2013guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin study group. J Clin Oncol. 2019;37:2835\u201345.","journal-title":"J Clin Oncol"},{"key":"875_CR15","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","volume":"390","author":"P Borchmann","year":"2017","unstructured":"Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, et al. PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2017;390:2790\u2013802.","journal-title":"Lancet."},{"key":"875_CR16","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol. 2012;30:2183\u20139.","journal-title":"J Clin Oncol"},{"key":"875_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372:311\u20139.","journal-title":"N Engl J Med"},{"key":"875_CR18","doi-asserted-by":"publisher","unstructured":"Kersten MJ, Driessen J, Zijlstra JM, Plattel WJ, Morschhauser F, Lugtenburg PJ, et al. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON\/LLPC Transplant BRaVE study. Haematologica. 2020; https:\/\/doi.org\/10.3324\/haematol.2019.243238. [Epub ahead of print].","DOI":"10.3324\/haematol.2019.243238"},{"key":"875_CR19","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.3324\/haematol.2018.196899","volume":"104","author":"A Hagenbeek","year":"2018","unstructured":"Hagenbeek A, Mooij H, Zijlstra J, Lugtenburg P, Van Imhoff G, Nijland M, et al. Phase 1 dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed\/refractory classical Hodgkin lymphoma: the Transplant BRaVE study. Haematologica. 2018;104:e151\u2013e3.","journal-title":"Haematologica."},{"key":"875_CR20","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1056\/NEJMp1615879","volume":"376","author":"J Beaver","year":"2017","unstructured":"Beaver J, Ison G, Pazdur R. Reevaluating eligibility criteria-balancing patient protection and participation in oncology trials. N Engl J Med. 2017;376:1504\u20135.","journal-title":"N Engl J Med"},{"key":"875_CR21","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/ejh.13090","volume":"101","author":"M Bjorkholm","year":"2018","unstructured":"Bjorkholm M, Weibull CE, Eloranta S, Smedby KE, Glimelius I, Dickman PW. Greater attention should be paid to developing therapies for elderly patients with Hodgkin lymphoma-A population-based study from Sweden. Eur J Haematol. 2018;101:106\u201314.","journal-title":"Eur J Haematol"},{"key":"875_CR22","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","volume":"15","author":"M Sant","year":"2014","unstructured":"Sant M, Minicozzi P, Mounier M, Anderson LA, Brenner H, Holleczek B, et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol. 2014;15:931\u201342.","journal-title":"Lancet Oncol."},{"key":"875_CR23","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1182\/blood-2010-08-302604","volume":"119","author":"J Sjoberg","year":"2012","unstructured":"Sjoberg J, Halthur C, Kristinsson SY, Landgren O, Nygell UA, Dickman PW, et al. Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973\u20132009. Blood. 2012;119:990\u20136.","journal-title":"Blood."},{"key":"875_CR24","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/ajh.24184","volume":"90","author":"I Glimelius","year":"2015","unstructured":"Glimelius I, Ekberg S, Jerkeman M, Chang ET, Bjorkholm M, Andersson TM, et al. Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992\u20132009-trends in cure proportions by clinical characteristics. Am J Hematol. 2015;90:1128\u201334.","journal-title":"Am J Hematol"},{"key":"875_CR25","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/bjc.2012.228","volume":"107","author":"EM Bessell","year":"2012","unstructured":"Bessell EM, Bouliotis G, Armstrong S, Baddeley J, Haynes AP, O\u2019Connor S, et al. Long-term survival after treatment for Hodgkin\u2019s disease (1973\u20132002): improved survival with successive 10-year cohorts. Br J Cancer. 2012;107:531\u20136.","journal-title":"Br J Cancer"},{"key":"875_CR26","doi-asserted-by":"publisher","first-page":"S164","DOI":"10.1097\/CEJ.0000000000000383","volume":"26","author":"M Solans","year":"2017","unstructured":"Solans M, Serra L, Renart G, Osca-Gelis G, Comas R, Vilardell L, et al. Incidence and survival of Hodgkin lymphoma patients in Girona (Spain) over three decades: a population-based study. Eur J Cancer Prev. 2017;26:S164\u2013S9.","journal-title":"Eur J Cancer Prev"},{"key":"875_CR27","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/bjh.16232","volume":"188","author":"I Lagerlof","year":"2020","unstructured":"Lagerlof I, Holte H, Glimelius I, Bjorkholm M, Enblad G, Erlanson M, et al. No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. Br J Haematol. 2020;188:685\u201391.","journal-title":"Br J Haematol"},{"key":"875_CR28","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/ije\/22.3.369","volume":"22","author":"LJ Schouden","year":"1993","unstructured":"Schouden LJ, H\u00f6ppener P, Van den Brandt PA, Knottnerus JA, Jager JJ. Completeness of cancer registration in Limburg, the Netherlands. Int J Epidemiol. 1993;22:369\u201376.","journal-title":"Int J Epidemiol"},{"key":"875_CR29","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","volume":"341","author":"DC Linch","year":"1993","unstructured":"Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial. Lancet. 1993;341:1051\u20134.","journal-title":"Lancet"},{"key":"875_CR30","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","volume":"36","author":"A Gallamini","year":"2018","unstructured":"Gallamini A, Tarella C, Viviani S, Rossi A, Patti C, Mul\u00e9 A, et al. Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 trial. J Clin Oncol. 2018;36:454\u201362.","journal-title":"J Clin Oncol"},{"key":"875_CR31","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1365-2796.2006.01677.x","volume":"260","author":"PW Dickman","year":"2006","unstructured":"Dickman PW, Adami HO. Interpreting trends in cancer patient survival. J Intern Med. 2006;260:103\u201317.","journal-title":"J Intern Med"},{"key":"875_CR32","unstructured":"Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Methodological note No.10. End Results Evaluation Section. Bethesda MD: National Cancer Institute. 1959."},{"key":"875_CR33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/bjh.14379","volume":"176","author":"L Liu","year":"2017","unstructured":"Liu L, Giusti F, Schaapveld M, Aleman B, Lugtenburg P, Meijnders P, et al. Survival differences between patients with Hodgkin lymphoma treated inside and outside clinical trials. A study based on the EORTC-Netherlands Cancer Registry linked data with 20 years of follow-up. Br J Haematol. 2017;176:65\u201375.","journal-title":"Br J Haematol"},{"key":"875_CR34","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1093\/annonc\/mdr578","volume":"23","author":"AM Evens","year":"2012","unstructured":"Evens AM, Antillon M, Aschebrook-Kilfoy B, Chiu BC. Racial disparities in Hodgkin\u2019s lymphoma: a comprehensive population-based analysis. Ann Oncol. 2012;23:2128\u201337.","journal-title":"Ann Oncol"},{"key":"875_CR35","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s10552-014-0374-6","volume":"25","author":"SL Glaser","year":"2014","unstructured":"Glaser SL, Clarke CA, Chang ET, Yang J, Gomez SL, Keegan TH. Hodgkin lymphoma incidence in California Hispanics: influence of nativity and tumor Epstein-Barr virus. Cancer Causes Control. 2014;25:709\u201325.","journal-title":"Cancer Causes Control"},{"issue":"Supplement_4","key":"875_CR36","doi-asserted-by":"publisher","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","volume":"29","author":"DA Eichenauer","year":"2018","unstructured":"Eichenauer DA, Aleman BMP, Andre M, Federico M, Hutchings M, Illidge T, et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Supplement_4):iv19\u2013iv29.","journal-title":"Ann Oncol"},{"key":"875_CR37","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","volume":"374","author":"P Johnson","year":"2016","unstructured":"Johnson P, Federico M, Kirkwood A, Fossa A, Berkahn L, Carella A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma. N Engl J Med. 2016;374:2419\u201329.","journal-title":"N Engl J Med"},{"key":"875_CR38","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet. 2002;359:2065\u201371.","journal-title":"Lancet"},{"key":"875_CR39","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","volume":"36","author":"AM Evens","year":"2018","unstructured":"Evens AM, Advani RH, Helenowski IB, Fanale M, Smith SM, Jovanovic BD, et al. Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. J Clin Oncol. 2018;36:3015\u201322.","journal-title":"J Clin Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0875-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0875-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0875-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:40:45Z","timestamp":1684604445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0875-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,28]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["875"],"URL":"https:\/\/doi.org\/10.1038\/s41375-020-0875-0","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,28]]},"assertion":[{"value":"19 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"There is no financial support for this work that could have influenced the outcomes described in the manuscript. However, particular authors report a potential conflict of interest, which is described below. MJK: Millennium\/Takeda: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Roche: Honoraria, Research Funding; Gilead: Honoraria; Kite Pharma: Honoraria; Novartis: Honoraria. PJL: Millennium\/Takeda: Consultancy, Research Funding; Servier: Consultancy, Research Funding; Roche: Consultancy; BMS: Consultancy; Sandoz: Consultancy; Genmab: Consultancy. JMZ: Consultant\/Advisor: Gilead, Roche, Takeda; Honoraria: Gilead, Roche, Takeda, Janssen. AGD: BMS: Research funding. All remaining authors have declared no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}